IP Library › Granted Patent US 9,855,318
Granted Patent B2
US 9,855,318 · App. 15/140,519 · Granted Jan 2, 2018

Fusion proteins

Inventors: David Bruce Baldwin (Carmel, IN); John Michael Beals (Indianapolis, IN); Jonathan Wesley Day (Carmel, IN); Craig Duane Dickinson (San Diego, CA); Andrew Ihor Korytko (Oceanside, CA); Gregory Alan Lazar (Pacifica, CA)
Assignee: Eli Lilly and Company
A61K38/28A61K38/16A61K38/26C07K14/001C07K14/62A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,855,318
App. No.
15/140,519
Granted
Jan 2, 2018
Kind
B2
Abstract

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.

Claims (4)

1. A homodimer of two fusion proteins of having the amino acid sequence of SEQ ID NO: 12.

2. A pharmaceutical composition comprising the homodimer of claim 1 .

3. A method of treating a patient with diabetes mellitus comprising administering to a patient in need thereof the homodimer of claim 1 .

4. A fusion protein having the amino acid sequence of SEQ ID NO: 12.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2026
From: BALDWIN, DAVID BRUCE; BEALS, JOHN MICHAEL; DAY, JONATHAN WESLEY; DICKINSON, CRAIG DUANE; KORYTKO, ANDREW IHOR; LAZAR, GREGORY ALAN
To: ELI LILLY AND COMPANY
Reel/Frame 073566/0155 →
Continuity (2)
Provisional Application 62158079 · May 7, 2015
Related Publication 20160324932A1 · Nov 10, 2016